Case Report

Journal of Gastroenterology

, Volume 43, Issue 5, pp 397-401

Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab

  • Keisuke OjiroAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Makoto NaganumaAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Hirotoshi EbinumaAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Hiroyoshi KunimotoAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Shinichiro TadaAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Haruhiko OgataAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Yasushi IwaoAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Hidetsugu SaitoAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University
  • , Toshifumi HibiAffiliated withDepartment of Internal Medicine, School of Medicine, Keio University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn’s disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn’s disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

Key words

Crohn’s disease infliximab HBV